Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘austria’ Category

Authors retract paper linking nuclear power to slow action on climate change

with 2 comments

climate-policyDo pro-nuclear energy countries act more slowly to curb the effects of climate change? That’s what a paper published in July in the journal Climate Policy claimed. But the hotly debated study was retracted last week after the authors came to understand that it included serious errors.

An August 22 press release about the original study has been retracted by the University of Sussex, and no longer appears on ScienceDaily. An archived version notes:   Read the rest of this entry »

Paper on pine tree genetics chopped for duplication

without comments

naslovna_vol6_no2A paper on genetic variability in Austrian pine trees apparently didn’t vary enough from other work.

The journal is now retracting the 2012 paper for having significant overlap with another paper published in 2008. Another researcher pointed out the duplication — which was unintentional, according to the note, the result of

an apparent failure in communication between the co-authors on both papers which caused the papers to be overlapped.

The overlapping papers share a first author, Aleksandar Lucic, who works at the Institute of Forestry in Serbia. The other author on both papers is Vasilije Isajev, at the Faculty of Forestry in Belgrade.

Analysis of Genetic Variability of Austrian Pine (Pinus nigra Arnold) in Serbia Using Protein Markers” was published in South-East European Forestry. The journal is not indexed on Thomson Scientific’s Web of Knowledge.

Here’s the retraction note:

Read the rest of this entry »

Authors retract abstract following misconduct by diabetes biotech

without comments

1Earlier this year, authors retracted a meeting abstract about a diabetes drug, following the revelation that the biotech that funded the trial committed misconduct.

The retraction was initiated by corresponding author Itamar Raz, at Hadassah Medical Center in Israel. The journal didn’t receive a response from any co-authors who were affiliated with the biotech company, Andromeda, so they were not included in the retraction process.

A few months after Hyperion Therapeutics acquired Andromeda’s diabetes drug DiaPep277, Hyperion announced it had evidence that some employees of Andromeda had “engaged in serious misconduct,” such as using un-blinded data and manipulating the analyses. Two relevant studies on the drug, designed to block the immune response that leads to type 1 diabetes, were retracted last year.

Here’s the retraction note for the abstract “Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis,’” published in the May issue of the journal:

Read the rest of this entry »

Pain paper scratched for authorship issues

with one comment

ejacoverA group of pain researchers in Austria has lost their 2014 paper in the European Journal of Anaesthesiology because one of the authors wasn’t, well, one of the authors.

The article, “Intravenous nonopioid analgesic drugs in chronic low back pain patients on chronic opioid treatment: A crossover, randomised, double-blinded, placebo-controlled study,” came from a team at the Medical University Vienna and Evangelical Hospital Vienna.

During the study, the authors tested whether intravenous infusions of nonopioid drugs (such as paracetamol, or Tylenol) helped people with chronic back pain who take opioids regularly. They found that people’s pain levels decreased in the days leading up to treatment, when they were receiving a placebo, but not after the actual infusion. The results likely stem from “expectation-related mechanisms,” they wrote. Read the rest of this entry »

Retractions follow revelations of misconduct by diabetes biotech

with 3 comments

diabetes careSeveral months after a drug company cancelled development of a potential diabetes cure because it found evidence that a biotech they had recently acquired had committed misconduct in studies of the drug, two retractions of relevant studies have appeared.

The research involves DiaPep277, which, as Josh Levy explained here in September, “would cause the immune system to stop attacking beta cells,” the cells in the pancreas that produce insulin. But Hyperion Therapeutics, which had acquired DiaPep277 developer Andromeda Biotech in June, announced in September that it had

uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result.

The retractions are both of papers published in Diabetes Care in May 2014. Here’s the notice for “Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial:” Read the rest of this entry »

Phantom authorship forces retraction of electron paper

with one comment

ULTRAMICUltramicroscopy has retracted a paper it published earlier this year after the corresponding author admitted to submitting the paper without the consent of his colleagues.

The article, “The post-peak spectra in electron energy loss near edge structure,” came from a group led by one Feng Tian, a materials scientist at Shanghai University for Science and Technology. The other authors were Peter Shattschneider and Micheal Stoger-Pollach, of the Vienna University of Technology. Except that they weren’t.

According to the retraction notice: Read the rest of this entry »

Written by amarcus41

December 8th, 2014 at 9:30 am

Cardiology researcher who admitted to fraud earns four-year funding ban

with 6 comments

dfg_logoA researcher who admitted in 2012 to “intentional and systematic manipulation” of data and had two papers retracted has been banned from funding by the German Research Foundation (DFG).

Dennis Rottländer, who will also be returning prize money he was awarded for the research, worked in Uta C. Hoppe’s lab at the University of Cologne. Hoppe, now at University Hospital Salzburg, remains under investigation, according to a statement from the DFG.

Excerpt: Read the rest of this entry »

Written by Ivan Oransky

July 23rd, 2014 at 1:33 pm

A partial retraction appears for former Salzburg crystallographer who admitted misconduct

with 8 comments

j imm april 2013A paper by a crystallographer fired from his university for misconduct has been partially retracted.

Last year, we covered the case of Robert Schwarzenbacher, formerly of Salzburg University. Schwarzenbacher had provided the crystallographic data for a paper in the Journal of Immunology, but those results raised questions with another crystallographer and prompted an investigation by the university.  Schwarzenbacher admitted he’d committed misconduct, although he recanted at one point, and was eventually fired.

Now, the authors have retracted the crystallographic data from the Journal of Immunology paper. Here’s the partial retraction, which is listed as a correction:
Read the rest of this entry »

Retraction for water researchers who ripped off dissertation

without comments

JCAMcoverA pair of engineers at Hohai University in Nanjing, China, has lost their 2012 paper in the Journal of Computational and Applied Mathematics. The reason: The article, “Study of the New Leon model for concrete failure,” wasn’t theirs to publish.

According to the retraction notice (which is dated September 2013 but has already appeared in ScienceDirect): Read the rest of this entry »

Written by amarcus41

April 2nd, 2013 at 12:02 pm

Paper — with longest title ever? — retracted for lack of author approval

without comments

inorgchimactaThe journal Inorganica Chimica Acta has retracted a paper it published earlier this year over an authorship dispute involving the lead researcher and his colleagues in France.

The title of the paper — whose bulk alone gave us a headache  — was “Reaction of a bidentate ligands (4,4′-dimethyl 2,2′-bipyridine) with planar-chiral chloro-bridged ruthenium: Synthesis of cis-dicarbonyl[4,4′-dimethyl-2,2′-bipyridine- κO1,κO2]{2-[tricarbonyl(η6-phenylene- κC1)chromium]pyridine-κN}ruthenium hexafluorophosphate” — and it purportedly came from a lab in Beirut.

However, as the retraction notice indicates, that’s not quite so:

Read the rest of this entry »

Written by amarcus41

March 15th, 2013 at 2:30 pm